Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
File version
Author(s)
Siskind, Dan
Winckel, Karl
Russell, Anthony W
Kisely, Steve
Smith, Greg
Hollingworth, Samantha
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
Clozapine is the most effective antipsychotic, but its use is tempered by adverse metabolic effects such as weight gain, glucose intolerance and type II diabetes. Current interventions do not facilitate compelling or sustained improvement in metabolic status. Recent studies suggest that glucagon-like peptide-1 (GLP-1) may play a key role in clozapine's metabolic effects, possibly suggesting that clozapine-associated obesity and diabetes are mediated independently through reduced GLP-1. As a result, GLP-1 agonists could show promise in reversing antipsychotic-induced metabolic derangements, providing mechanistic justification that they may represent a novel approach to treat, and ultimately prevent, both diabetes and obesity in patients on clozapine. GLP-1 agonists are already used for diabetes, and they provide a unique combination of glycaemic improvement and metabolically relevant weight loss in diabetic and non-diabetic patients, in the context of a currently favourable safety proifile. Using GLP-1 agonists for clozapine-associated obesity and diabetes could be a potentially effective intervention that may reduce cardiometabolic morbidity and mortality in this vulnerable patient population.
Journal Title
Journal of Psychopharmacology
Conference Title
Book Title
Edition
Volume
30
Issue
3
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Biomedical and clinical sciences
Psychology
Science & Technology
Life Sciences & Biomedicine
Clinical Neurology
Neurosciences
Pharmacology & Pharmacy
Persistent link to this record
Citation
Mayfield, K; Siskind, D; Winckel, K; Russell, AW; Kisely, S; Smith, G; Hollingworth, S, Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes, Journal of Psychopharmacology, 2016, 30 (3), pp. 227-236